Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.

Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study

Cavallo F.;Ferrero S.;
2019

Abstract

Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.
134
10
798
801
http://www.bloodjournal.org/content/bloodjournal/134/10/798.full.pdf
Early progression; marginal zone lymphoma
Luminari S.; Merli M.; Rattotti S.; Tarantino V.; Marcheselli L.; Cavallo F.; Varettoni M.; Bianchi B.; Merli F.; Tedeschi A.; Cabras G.; Re F.; Visco C.; Delamain M.T.; Cencini E.; Spina M.; Ferrero S.; Ferrari A.; Deodato M.; Mannina D.; Annibali O.; Rago A.; Orsucci L.; Defrancesco I.; Frigeni M.; Cesaretti M.; Arcaini L.
File in questo prodotto:
File Dimensione Formato  
Luminari.post-print.docx

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 139.82 kB
Formato Adobe PDF
139.82 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Luminari.post-print.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 224.82 kB
Formato Adobe PDF
224.82 kB Adobe PDF Visualizza/Apri
pubb 2.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 688.5 kB
Formato Adobe PDF
688.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1732697
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 21
social impact